ArticleScientific reports2025
Identification and single-cell analysis of prognostic genes related to mitochondrial and neutrophil extracellular traps in bladder cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The development of bladder cancer (BLCA) is associated with mitochondrial dysfunction and neutrophil extracellular traps (NETs); however, the relationship between mitochondrial function and NET formation in BLCA remains poorly understood. In this study, BLCA datasets, along with mitochondria- and NET-related genes, were retrieved from public databases and existing literature. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and protein-protein interaction (PPI) networks were applied to identify prognostic genes. A prognostic model incorporating six key genes (CCDC80, NIBAN1, CSPG4, PDGFRA, MAP1A, and PCOLCE2) was established through machine learning methods and univariate Cox regression analysis. This model demonstrated strong prognostic accuracy for BLCA, further validated by a nomogram exhibiting excellent predictive performance. Using the established prognostic model, patient samples were stratified into high-risk (HRG) and low-risk groups (LRG). Significant differences in immune cell infiltration-including eosinophils and 24 other immune cell types-were observed between these groups. The risk scores strongly correlated with multiple immune cells, notably natural killer cells. Furthermore, immune checkpoint analysis revealed significant upregulation of only three checkpoint genes (TNFRSF14, TNFRSF25, and VEGFA) in the LRG. Additionally, fibroblasts were identified as key cells through analysis of the GSE222315 dataset, with prognostic gene expression varying significantly during fibroblast differentiation. Experimental validation via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) confirmed that all six prognostic genes were significantly downregulated in BLCA clinical samples collected for this study. Overall, the study highlights six novel prognostic biomarkers and presents a robust predictive model, providing new insights into BLCA prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.